. . . . . . . . . "Topotecane"@en . . . . . . . . . "investigational"@en . . . "For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy."@en . . . . . . . . . . . " "@en . " "@en . . . . . . . . "119413-54-6"@en . . . . "The primary anticipated complication of overdosage would consist of bone marrow suppression."@en . . "# Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C: Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9885371 # Herben VM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996 Aug;31(2):85-102. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8853931 # Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ: An overview of the clinical pharmacology of topotecan. Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-12-S5-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9122737"@en . . . . "approved"@en . . "Venkata Raghavendra Palle, Sekhar Nariyam, Lankeshwara Matti, \"PROCESS FOR PREPARING TOPOTECAN.\" U.S. Patent US20070149783, issued June 28, 2007."@en . . . . "Renal clearance is an important determinant of topotecan elimination. In a mass balance/excretion study in 4 patients with solid tumors, the overall recovery of total topotecan and its N-desmethyl metabolite in urine and feces over 9 days averaged 73.4 \u00B1 2.3% of the administered IV dose. Fecal elimination of total topotecan accounted for 9 \u00B1 3.6% while fecal elimination of N-desmethyl topotecan was 1.7 \u00B1 0.6%."@en . "2-3 hours"@en . . "Topotecan"@en . "Humans and other mammals"@en . . . "Topotecanum"@en . "Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (\u22121) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme\u2013substrate complex, Topotecan acts as an uncompetitive inhibitor."@en . . . . . . . . "An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. [PubChem]"@en . "9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin"@en . . . . . . "35%"@en .